Hoarseness at 20 to 24 days · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in hoarseness at 20 to 24 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Complete clearance · people with scabies, over 5 years of ageLocation: India
Oral ivermectin 200 μg/kg (1 dose) showed no clear difference in complete clearance ‐ week 4 compared with oral ivermectin 200 μg/kg (2 doses) (high certainty).
1 finding from 1 review
1Sharma 2011. · people with scabies, over 5 years of ageLocation: India
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Resumption of menstrual regularity · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
no estimate extracted
2006 participants
GRADE not reported
Resumption of spontaneous ovulation · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
no estimate extracted
2006 participants
GRADE not reported
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Improvement in acne severity · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
no estimate extracted
2006 participants
GRADE not reported
Improvement in testosterone level (nmol/L) after 6 months' treatment · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Adverse effects · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
no estimate extracted
2006 participants
GRADE not reported
Total effectiveness rate (Analysis 1.1) Clinician's rating · atopic eczema
Combination of oral and topical CHM showed no clear difference in total effectiveness rate (Analysis 3.1) Clinician's rating compared with same oral CHM (low certainty).
1 finding from 1 review
Overall severity score (Analysis 1.3) Clinician's rating. Scale from 1 to 80 · atopic eczema
1 finding from 1 review
QoL · atopic eczema
1 finding from 1 review
Adverse events (Analysis 1.7) Participant's report · atopic eczema
Combination of oral and topical CHM showed no clear difference in adverse events (Analysis 3.7) Participant's report compared with same oral CHM (low certainty).
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review
Skin lesion score (Analysis 3.4) Clinician's rating. Scale from 0 to 24 · atopic eczema
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in complete remission Time frame: 4 weeks compared with oral steroids alone (moderate certainty).
2 findings from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in complete or partial remission Time frame: 24 weeks to end of treatment compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Relapse · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in relapse Time frame: 24 weeks compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: death · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review